Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Cost of Revenue (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Cost of Revenue for 10 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 8.3% year-over-year to $17.1 million, compared with a TTM value of $49.1 million through Dec 2025, up 4.2%, and an annual FY2025 reading of $49.1 million, up 4.2% over the prior year.
  • Cost of Revenue was $17.1 million for Q4 2025 at Heron Therapeutics, up from $11.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $39.0 million in Q3 2021 and bottomed at $7.5 million in Q2 2024.
  • Average Cost of Revenue over 5 years is $17.0 million, with a median of $14.1 million recorded in 2021.
  • The sharpest move saw Cost of Revenue skyrocketed 211.33% in 2021, then tumbled 65.18% in 2023.
  • Year by year, Cost of Revenue stood at $24.5 million in 2021, then fell by 27.41% to $17.8 million in 2022, then plummeted by 30.64% to $12.3 million in 2023, then soared by 51.4% to $18.7 million in 2024, then fell by 8.3% to $17.1 million in 2025.
  • Business Quant data shows Cost of Revenue for HRTX at $17.1 million in Q4 2025, $11.9 million in Q3 2025, and $11.6 million in Q2 2025.